Table 1. Clinical outcomes and most common AEs (≥3 grade).
| Variables | Values | |
|---|---|---|
| Anlotinib | Sunitinib | |
| Clinical efficacy (months) | ||
| Median OS | 30.9 | 30.5 |
| Median PFS | 17.5 | 16.6 |
| Total AEs (grade ≥3) (%) | 28.9 | 55.8 |
| Adverse event | ||
| Hypertension | 13.3 | 25.6 |
| Hand-foot syndrome | 3.3 | 14 |
| Diarrhea | 1.1 | 0 |
| Stomatitis | 2.2 | 2.3 |
| Laboratory abnormality | ||
| Increased triglyceride | 4.4 | 7.0 |
| Increased cholesterol | 1.1 | 2.3 |
| Increased creatinine | 0 | 2.3 |
| Hypophosphatemia | 3.3 | 9.3 |
| Thrombocytopenia | 0 | 11.6 |
| Increased alkaline phosphatase | 2.2 | 0 |
| Leukopenia | 0 | 2.3 |
| Anemia | 2.2 | 4.7 |
| Neutropenia | 0 | 9.3 |
| Lymphopenia | 0 | 4.7 |
OS, overall survival; PFS, progression-free survival; AE, adverse event